Gürer E. E., Şentürk Çiftçi H., Oğuz S. R., İzgi D., Beşışık S.

Society of hematologic oncology, İstanbul, Turkey, 5 - 07 May 2023, pp.26

  • Publication Type: Conference Paper / Summary Text
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.26
  • Istanbul University Affiliated: Yes


Objective Studies have shown that cytokines are effective in the pathogenesis and treatment processes of Multiple Myeloma (MM). CXCR4 is a pleiotropic chemokine receptor that acts through its ligand CXCL12 to regulate various physiological processes. CXCR4-CXCL12 interaction contributes to different vital biological processes by activating various extracellular and intracellular signaling pathways. The aim of this study was to assess the potential role of CXCL12 on the pathogenesis of MM.

Case Report Methodology STRING/GeneMANIA/KEGG PATHWAY/GSEA/MSigDB for gene set enrichment analysis for gene protein and pathway interaction, TargetScan/miRDB for miRNAs targeting CXCL12, Blood eQTL Browser/ to target CXCL12 BIOS/QTLdb, GRASP and GWAS CXCL12 and miRNA region SNPs were used for disease associations.

Results Five hundred and ninety-three miRNAs were identified by miRDB. As a result of examining the disease associations of SNPs from each miRNA gene region in GWAS databases, it was determined that P<7E-40 for B lymphoblastic leukemia/lymphoma. CXCL12 roles at Leukocyte chemotaxis (FDR=3.33e-08), Leukocyte migration (FDR=3.91e-08), Lymphocyte chemotaxis (FDR=0.00050). It is involved in MM disease using the chemokine signaling pathway (FDR=5.93e-08).

Conclusion It is thought that CXCL12 may play a strong role in MM. In this sense, it can also be a referral for treatment. To understand the mechanism of CXCL12 in MM disease, experimental studies with large cohorts should be carried out with the help of bioinformatics databases.